Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 14550 participants.
Also called NCT06008756
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 14,550 participants
- Sponsor
- Registry
-
NCT06008756 -
jRCT2071230064 -
2022-502781-24-00 -
U1111-1285-4245
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Denmark, France, Germany, Hong Kong SAR China, Hungary, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Norway, Peru, Poland, Puerto Rico, South Africa, South Korea, Spain, Taiwan, Türkiye, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06008756. Randomized; triple masking; primary purpose treatment. Start 2023-10-09 (actual); primary completion 2029-11-29 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
- Condition
- Arteriosclerosis
- Condition
- Hypercholesterolaemia
- Intervention (Drug)
- Enlicitide Decanoate
- Intervention (Drug)
- Placebo
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct06008756- Content hash
1cbe42b43ecd0a3cf28deefe7a7eb17ef9b7fd4249562567c88876c324d4727d